Background
Non-invasive ventilation (NIV) is a standard of care for hypercapnic chronic respiratory failure (CRF). Obstructive sleep apnea (OSA) frequently contribute to hypoventilation in CRF. CPAP improves hypercapnia in selected COPD and obese patients. We describe the profile of patients switching from NIV to CPAP in a cohort of patients on long-term NIV and identify factors associated with a successful switch.
Methods
The observational research protocol evaluation committee of the French Pneumology Society approved this case-control study (CEPRO 2022-015). We compared 88 consecutive candidates for a NIV-CPAP switch with 266 controls among 394 ventilated patients treated at the Dijon University Hospital between 2015 and 2020. They followed a standardized protocol including a poly(somno)graphy recorded after NIV withdrawal for three nights. CPAP trial was performed if severe OSA was confirmed. Recurrent hypoventilation was checked after one night and one month under CPAP.
Results
Patients were 53% males, median age 65 [56–74] years, and median BMI 34 [25-38.5] kg/m2. Sixty seven percent of patients were safely switched and remained on CPAP. The probability of a NIV-CPAP switch was correlated to older age (OR:1.3 [1.01–1.06]), CRF etiology (OR for COPD:20.37 [4.2–98,72], obesity:7.31 [1.58–33.74]), circumstances of NIV initiation (OR for acute exacerbation:11.64 [2.03–66.62]), lower pressure support (OR:0.90 [0.73–0.92]), lower baseline PaCO2 (OR:0.85 [0.80–0.91]) and lower compliance (OR:0.76 [0.64–0.90]). Pressure support level was the only factor associated with the outcome of the NIV-CPAP switch.
Conclusions
A NIV-CPAP switch is possible in real life conditions in stable obese and COPD patients with underlying OSA.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.